Podcast Summary: "Amazon’s $38 Billion OpenAI Deal — And Why We Were Already Bullish on the Stock"

Prof G Markets, Vox Media Podcast Network, November 4, 2025
Hosts: Ed Elson, Scott Galloway
Key Guests: Ryan Peterson (Flexport), Dan Primack (Axios)

Episode Overview

This episode tackles three major market-moving stories:

• The ongoing debate and legal battle over US tariffs and their economic impact, featuring Ryan Peterson of Flexport.
• Kimberly-Clark's $48 billion acquisition of Kenview, with analysis by Axios's Dan Primack.
• The significance of Amazon's $38 billion cloud-compute deal with OpenAI, and a deep-dive into why the hosts remain bullish on Amazon's stock.

Key Discussion Points & Insights

1. Tariff Paralysis, Prices & Winners/Losers

(02:02 – 16:34) Guest: Ryan Peterson, CEO of Flexport

• State of 'Paralysis' in Business

  • Companies are reluctant to make major supply chain shifts due to changing tariffs:
    • “It was just very difficult for people to make decisions because it was all changing so fast in terms of which countries were being hit with what duty rates.” (Ryan Peterson – 04:54)
    • Recent tariff decreases on China actually left some who moved manufacturing elsewhere at a disadvantage.
  • “Paralysis before was the right answer, because if you did move your production to India, then all of a sudden your tariffs are higher than if you would have kept it in China.” (Ryan Peterson – 05:28)

• Tariffs’ Effect on Prices

  • Brands have passed along some price increases, but are cautious due to uncertain demand.
    • “Brands are always very reluctant to increase price because...they can’t afford to shrink.” (Ryan Peterson – 06:26)
  • Goods-sector recession: lower freight volumes and import competition may even force prices down due to fierce competition.

• Inflation and 'Hidden' Tariff Impact

  • Many argue inflation data shows tariffs aren’t a huge problem, but Peterson warns of delays and points out widespread customs fraud:
    • “Our analysis is that around 10% of all freight that’s coming into the United States from China has shifted terms...just massive amounts of fraud.” (Ryan Peterson – 08:57)
    • This evasion could be muting inflation and hiding tariff impacts.

• Winners and Losers

  • Winners: Agile companies, customs brokers (like Flexport), and Latin American manufacturers (excluding Brazil).
  • Losers: U.S. e-commerce companies relying on the de minimis exemption, fulfillment centers in Mexico/Canada, consumers, and advocates of free trade.
  • “E-commerce brands are really suffering, especially people that were using what’s called the de minimis. That’s gone away. It’s really hit hard these fulfillment center jobs in Mexico...I suspect you’ll probably see some bankruptcies.” (Ryan Peterson – 12:16)

• Looking Ahead: Court Decisions & Tariff Future

  • Supreme Court outcome highly uncertain. Polymarket betting suggests a 65% chance the administration loses and refunds are issued.
  • Both hosts agree: tariffs could soon be reversed or at least greatly reduced depending on legal/political outcomes.
    • “I think the Supreme Court’s a political body more than it is a legal one in a lot of ways.” (Ryan Peterson – 15:46)

2. Kimberly-Clark’s $48 Billion Kenview Buyout

(21:14 – 27:44) Guest: Dan Primack, Axios

• Deal Rationale & Investor Response

  • Kimberly-Clark wants to diversify into health and wellness as consumers age, but investors are spooked by the scale and litigation risk.
    • “The strategic rationale does make a certain amount of sense… But there's these massive litigation risks, which is what I think the investors were freaking out about.” (Dan Primack – 21:34)

• Kenview’s Stock Performance and Risks

  • Stock down 35% since spin-off from J&J, mainly due to ongoing and potential litigation (talc, Tylenol-autism claims).
    • “Even if Kenview...wins every single one...It's still a massive cost and it’s a massive time suck.” (Dan Primack – 23:25)

• Antitrust and Deal Mechanics

  • No major antitrust issues expected, but the Tylenol situation presents a wild card, particularly with current administration's regulatory posture.
  • The deal assumes all of Kenview’s litigation risks—no carve-outs as seen in some previous mergers.

• Tylenol Controversy as Deal Catalyst?

  • The negative press may have led to a discounted purchase price for Kimberly-Clark.
    • “Do you think it's possible that they looked at the Tylenol situation and they said, actually, the stock's at a discount. We're not so worried about the litigation...?” (Ed Elson – 26:03)
    • Primack: Unclear until SEC filings reveal details, but likely the controversy made Kenview more attractive from a value perspective.

3. Amazon’s $38 Billion OpenAI Deal & Bullish Case

(27:49 – End)

• Deal Details and Context

  • Amazon signs a 7-year, $38 billion agreement to host OpenAI’s projects using Nvidia chips in AWS data centers.
  • Market reaction: Amazon stock up 4% (adding $100 billion in market cap); Nvidia also gains.
  • “Another week, another blockbuster deal involving OpenAI…” (Ed Elson – 27:58)

• Why This Matters / Comparison to Other Deals

  • The deal is substantial but not the largest OpenAI has done (Oracle and AMD far larger).
  • Signals a partial pivot away from Microsoft, as OpenAI diversifies cloud partners.

• The Bullish Amazon Thesis

  • AI Leader Status: AWS is the world’s largest cloud player—indispensable for current AI workloads.

    • “Despite that, Amazon has, for whatever reason, been viewed as an AI laggard...but you should think of Amazon.” (Ed Elson – 28:50)
    • Amazon’s custom Trainium chips are seeing explosive growth (+150% last quarter).

  • Efficiency Play:

    • Mimicking Meta’s “year of efficiency,” Amazon cutting workforce; Wall Street rewards cost discipline.
    • “Amazon’s plan is to mow it down.” (Ed Elson – 29:27)

  • Valuation (Mean Reversion):

    • Amazon’s price-to-earnings multiple is near historical lows (34x now vs. 60x five years ago).
    • Growth prospects (cloud, AI, Project Kuiper) aren’t weaker—potential for multiple expansion as recognition grows.

  • Final Take:

    • Though stock has already run after the initial call and deal news, the hosts remain bullish:
      • “At $254. We like the stock in some long Amazon.” (Ed Elson – 30:41)

Notable Quotes & Moments

• On business paralysis under tariffs:

  • “Paralysis before was the right answer... people who acted too quickly... are now going, ‘Wait, China’s got lower D rates.’” (Ryan Peterson – 05:28)

• On customs fraud as tariff evasion:

  • “We’re seeing around 10% of US trade has shifted terms in a way that indicates just massive amounts of fraud.” (Ryan Peterson – 09:17)

• On dealmaking in litigation-heavy environments:

  • “Even if Kenview...wins every single one...It's still a massive cost and it’s a massive time suck.” (Dan Primack – 23:25)

• On the undervalued perception of Amazon as an AI play:

  • “Generally speaking, you don’t think of Amazon, but you should think of Amazon.” (Ed Elson – 28:50)

Timeline of Important Segments

| Timestamp | Segment / Topic | |------------|---------------------------------------------------------------------------------| | 02:02 | Tariffs: Supreme court, supply chain impacts, business paralysis (w/ Peterson) | | 04:54 | Clarity on new tariffs, regret over rapid supply chain moves | | 06:12 | Tariffs’ effects on pricing, freight indicators | | 08:42 | Inflation measurements & customs fraud | | 10:28 | Winners/losers in the changing tariff landscape | | 12:16 | The end of “de minimis” exemptions, impact on e-commerce, cross-border jobs | | 14:35 | Crystal ball: Supreme Court, likelihood of tariff reversal | | 21:14 | Kimberly-Clark / Kenview $48B M&A (w/ Primack) | | 23:25 | Kenview's legal risks, deal premium | | 24:35 | Antitrust considerations and deal structure | | 26:03 | Did Tylenol-autism panic drive cheap deal pricing? | | 27:49 | Amazon’s $38B OpenAI deal, market reaction | | 28:50 | Amazon as AI leader, Trainium chips, AWS scale | | 29:27 | “Year of efficiency” echoes, valuation case for Amazon | | 30:41 | Bullish closing note: Buy Amazon |

Tone and Language

• Direct, analytical, and occasionally wry—true to Prof G Markets’ “no mercy, no malice” branding.
• Real-world business and market perspectives, focused on actionable insight and challenging easy narratives.

Bottom Line:
This episode expertly navigates three hot market stories—explaining the real business effects of trade policy, the risks and logic behind a huge pharma M&A deal, and why Amazon may be underappreciated as the AI cloud arms race heats up. The hosts blend market insight, skepticism, and punchy analysis, giving listeners a clear sense of why these stories matter now and how they could shape portfolios in the months ahead.